| Altername | ICF; ICF1; M.HsaIIIB |
| Recommended Dilutions | WB: 1:1000-1:2000, ICC/IF: 1:20-1:50 |
| Formulation | Store at -20°C. Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40%Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt. |
| Purification | Affinity Purification |
| Storage/Stability | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. |
| Specificity | IgG |
| Molecular Weight | 96 kDa |
| Immunogen | A synthetic peptide of human Dnmt3b |
| Conjugate | Unconjugated |
| Modification | Unmodification |
Background
CpG methylation is an epigenetic modification that is important for embryonic development, imprinting, and X-chromosome inactivation. Studies in mice have demonstrated that DNA methylation is required for mammalian development. This gene encodes a DNA methyltransferase which is thought to function in de novo methylation, rather than maintenance methylation. The protein localizes primarily to the nucleus and its expression is developmentally regulated. Mutations in this gene cause the immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome. Eight alternatively spliced transcript variants have been described. The full length sequences of variants 4 and 5 have not been determined.
Reviews
There are no reviews yet.